Cefaclor Capsules — Competitive Intelligence Brief

Cefaclor Capsules (Cefaclor Capsules) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Second-generation cephalosporin. Area: Infectious Disease.

marketed Second-generation cephalosporin Penicillin-binding proteins (PBPs) Infectious Disease Small molecule

Target snapshot

Cefaclor Capsules (Cefaclor Capsules) — Fundacion Clinic per a la Recerca Biomédica. Cefaclor is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cefaclor Capsules TARGET	Cefaclor Capsules	Fundacion Clinic per a la Recerca Biomédica	marketed	Second-generation cephalosporin	Penicillin-binding proteins (PBPs)
Cefmetazole (drug)	Cefmetazole (drug)	National Taiwan University Hospital	marketed	Second-generation cephalosporin	Penicillin-binding proteins (PBPs)
I.V cefuroxime 750 mg*3/d for 2 days	I.V cefuroxime 750 mg*3/d for 2 days	Western Galilee Hospital-Nahariya	marketed	Second-generation cephalosporin	Penicillin-binding proteins (PBPs)
Cefuroxime (750mg) I.V	Cefuroxime (750mg) I.V	Hospital Universitari Vall d'Hebron Research Institute	marketed	Second-generation cephalosporin	Penicillin-binding proteins (PBPs)
P.O cefuroxime 500 mgx2/d for 5 days	P.O cefuroxime 500 mgx2/d for 5 days	Western Galilee Hospital-Nahariya	marketed	Second-generation cephalosporin	Penicillin-binding proteins (PBPs)
Comparator: cefotetan	Comparator: cefotetan	Merck Sharp & Dohme LLC	phase 3	Second-generation cephalosporin	Penicillin-binding proteins (PBPs)
Continuous infusion of cefoxitin	Continuous infusion of cefoxitin	Poitiers University Hospital	phase 3	Second-generation cephalosporin	Penicillin-binding proteins (PBPs)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Second-generation cephalosporin class)

1. Poitiers University Hospital · 3 drugs in this class
2. Western Galilee Hospital-Nahariya · 2 drugs in this class
3. Fundacion Clinic per a la Recerca Biomédica · 1 drug in this class
4. Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class
5. Merck Sharp & Dohme LLC · 1 drug in this class
6. National Taiwan University Hospital · 1 drug in this class